Overexpression of ribosome binding protein 1 (RRBP1) in breast cancer

Clinical Proteomics

Akhilesh Pandey⁷  Sujatha Mohan⁶  Jagadeesha Maharudraiah¹  Y L Ramachandra⁴  Deepthi Telikicherla⁵  Arivusudar Marimuthu³  Manoj Kumar Kashyap³  Juan Carlos Roa² 

[1] Institute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Pathology and Laboratory Medicine, Icon Hospitals, Bangalore, IndiaManipal University, Manipal, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Pathology and Laboratory Medicine, Icon Hospitals, Bangalore, IndiaManipal University, Manipal, IndiaDepartment of Pathology and Laboratory Medicine, Icon Hospitals, Bangalore, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Pathology and Laboratory Medicine, Icon Hospitals, Bangalore, IndiaManipal University, Manipal, IndiaManipal University, Manipal, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Pathology and Laboratory Medicine, Icon Hospitals, Bangalore, IndiaManipal University, Manipal, India;Department of Pathology, Universidad de La Frontera, Temuco, ChileDepartment of Pathology, Universidad de La Frontera, Temuco, ChileDepartment of Pathology, Universidad de La Frontera, Temuco, Chile;Institute of Bioinformatics, International Tech Park, Bangalore, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, India;Department of Biotechnology, Kuvempu University, Shankaraghatta, IndiaDepartment of Biotechnology, Kuvempu University, Shankaraghatta, IndiaDepartment of Biotechnology, Kuvempu University, Shankaraghatta, India;Institute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Biotechnology, Kuvempu University, Shankaraghatta, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Biotechnology, Kuvempu University, Shankaraghatta, IndiaDepartment of Biotechnology, Kuvempu University, Shankaraghatta, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaDepartment of Biotechnology, Kuvempu University, Shankaraghatta, India;Institute of Bioinformatics, International Tech Park, Bangalore, IndiaResearch Unit for Immunoinformatics, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, JapanInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaResearch Unit for Immunoinformatics, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, JapanResearch Unit for Immunoinformatics, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, JapanInstitute of Bioinformatics, International Tech Park, Bangalore, IndiaResearch Unit for Immunoinformatics, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, Japan;McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USADepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, USAMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USA

关键词: Breast neoplasms;    ES130;    p180;    180 kDa ribosome receptor homolog;    Endoplasmic reticulum membrane protein;    Immunohistochemistry;    Biomarker;    Early detection;   

DOI  :  10.1186/1559-0275-9-7

来源: Humana Press Inc

【 摘 要 】

Abstract

The molecular events that lead to malignant transformation and subsequent metastasis of breast carcinoma include alterations in the cells at genome, transcriptome and proteome levels. In this study, we used publicly available gene expression databases to identify those candidate genes which are upregulated at the mRNA level in breast cancers but have not been systematically validated at the protein level. Based on an extensive literature search, we identified ribosome binding protein 1 (RRBP1) as a candidate that is upregulated at the mRNA level in five different studies but its protein expression had not been investigated. Immunohistochemical labeling of breast cancer tissue microarrays was carried out to determine the expression of RRBP1 in a large panel of breast cancers. We found that RRBP1 was overexpressed in 84% (177/219) of breast carcinoma cases tested. The subcellular localization of RRBP1 was mainly observed to be in the cytoplasm with intense staining in the perinuclear region. Our findings suggest that RRBP1 is an interesting molecule that can be further studied for its potential to serve as a breast cancer biomarker. This study also demonstrates how the integration of biological data from available resources in conjunction with systematic evaluation approaches can be successfully applied to clinical proteomics.

【 授权许可】

Unknown